Forecast

The analysts' average price target is +7,09€ (+29,38%). The median is +6,66€ (+21,53%).

Buy	15
Hold	27
Sell	0

News Go to news feed

Teladoc Health appoints Mark V. Anquillare to the board of directors

Teladoc Health has appointed Mark V. Anquillare, former president and COO of Verisk Analytics, to its board of directors. He will serve on the audit and compensation committees and brings more than 30 years of experience in finance and leadership roles, including overseeing Verisk’s 2009 IPO. Anquillare also sits on several other boards; Teladoc Health provides virtual healthcare services through partnerships with insurers, employers and health systems. » More on de.investing.com
Teladoc reports revenue decline and cuts annual forecast – stock falls sharply

Teladoc reported Q2 revenue of $606.9 million, missing the analyst consensus of about $615 million, while adjusted EPS of -$0.21 beat expectations. Consumer segment BetterHelp shrank 12% to $212.6 million. For Q3 management expects revenue of $569–609 million and lowered the full-year guidance to $2.36–2.45 billion (previously $2.48–2.58 billion), which weighed heavily on the stock in premarket trading. CEO Chuck Divita cited provider capacity constraints as the reason for weaker revenue realization; over the past six months there have been only insider sales. » More on de.investing.com
Teladoc plunges about 24% after Q2 results and weak outlook

Teladoc reported a Q2 EPS loss of -$0.21 with revenue of $606.9 million, missing consensus. The Q3 outlook of $569–609 million is well below the $629 million consensus, and the full-year loss forecast was lowered to -$1.00 to -$0.75. The combination of a revenue miss, reduced guidance and continued drag from the BetterHelp segment triggered the sharp share decline. Investors are now awaiting management comments on the conference call for signs of a return to revenue growth. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Teladoc Health has already paid 0,26€ in dividends. The last payout was in March 2022.

Financials

In the last quarter, Teladoc Health had revenue of 531.80m€ and net profit of −34.09m€

(EUR)	Jun 2026	YoY
Revenue	+531.80m	0,81%
Gross profit	+545.08m	45,56%
Net profit	−34.09m	23,03%
EBITDA	−109.12m	4.907,89%

Fundamentals

Metric	Value
Market capitalization	+968.36m€
Number of shares	181.68m
52-week high/low	+8,49€ - +3,78€
Dividends	No
Beta	2,13
P/E ratio	−6,27
PEG ratio	−0,38
P/B ratio	+0,85
P/S ratio	+0,45

Company profile

Teladoc Health, Inc. bietet virtuelle Gesundheitsdienste in den Vereinigten Staaten und international an. Das Unternehmen bietet ein Portfolio von Dienstleistungen und Lösungen für nicht dringende, episodische, chronische und komplizierte medizinische Erkrankungen, einschließlich Diabetes, Bluthochdruck, chronische Nierenerkrankungen, Krebs, Herzinsuffizienz und psychische Erkrankungen. Das Unternehmen bietet eine Reihe von Programmen und Dienstleistungen an, darunter Lösungen für die telemedizinische Grund- und Spezialversorgung, das Management chronischer Erkrankungen, medizinische Expertendienste, Lösungen für psychische Erkrankungen sowie Plattform- und Programmdienste. Das Unternehmen bedient Arbeitgeber, Gesundheitspläne, Krankenhäuser und Gesundheitssysteme, Versicherungs- und Finanzdienstleistungsunternehmen sowie Einzelmitglieder. Es bietet seine Produkte und Dienstleistungen unter den Marken Teladoc, Livongo und BetterHelp an. Das Unternehmen war früher als Teladoc, Inc. bekannt und änderte im August 2018 seinen Namen in Teladoc Health, Inc. Das Unternehmen wurde im Jahr 2002 gegründet und hat seinen Hauptsitz in Purchase, New York.

Name	Teladoc Health
CEO	Charles Divita
Headquarters	New York, ny USA
Website	teladochealth.com
Sector	Health Care
Industry	Health Care Providers & Services
IPO	06/30/2015
Employees	5.124